Cancer Research Technology

CRT, Merck to develop inhibitors for cancer and blood disorders

Tuesday, February 2, 2016

Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research U.K., has entered into a license agreement with MSD, known as Merck in the U.S. and Canada, to develop inhibitors of protein arginine methyltransferase 5 (PRMT5). These new drugs, which potentially have clinical applications in both cancer and non-cancer blood disorders, have been developed by the Australian Cooperative Research Center (CRC) for Cancer Therapeutics (CTx) with support from the Wellcome Trust and CRT.​

[Read More]

Forma Therapeutics, Cancer Research Technology form two virtual companies

Wednesday, March 25, 2015

Forma Therapeutics, headquartered in Watertown, Mass., and Cancer Research Technology (CRT) have formed two new virtual Asset Discovery and Development Companies (ADDCos) with novel chemical matter targeting undisclosed deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, drug discovery scientists and a development network.

[Read More]

Syncona, UCLB form Autolus cancer immunotherapy company

Friday, January 23, 2015

Syncona, a London-based subsidiary of the Wellcome Trust, and UCL Business, the wholly-owned technology transfer company of University College London (UCL), have announced the creation of Autolus, a London-based biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies for hematological and solid tumors. Autolus is founded upon the work of Dr. Martin Pule, an academic clinical hematologist and thought-leader in T-cell engineering. Syncona has committed $33.5 million to Autolus in a Series A financing. Dr. Christian Itin, former CEO of Micromet, has joined the company as chairman.

[Read More]

BioInvent inks agreement with Cancer Research U.K., CRT and LLR

Wednesday, January 21, 2015

BioInvent International, a research-based pharmaceutical company based in Sweden, has reached an agreement with Cancer Research U.K.Cancer Research Technology (CRT), the charity’s development and commercialization arm, and Leukemia & Lymphoma Research (LLR) to take its investigational drug, BI-1206, into a collaborative phase I/II trial for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

[Read More]